Jasper Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jasper Therapeutics, Inc. (JSPR) on July 31, 2026. The report addresses Item 8.01 (Other Events) regarding the issuance of Contingent Value Rights (CVRs) to shareholders in connection with the Company's acquisition of Kira Pharmaceuticals, which closed on July 16, 2026.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only specific financial figure disclosed relates to a potential future contingent payment.
- Contingent Milestone Payment: $30.0 million
- Payment Trigger: Issuance of a Priority Review Voucher by the FDA for the drug briquilimab.
- Expiration Date: December 31, 2028.
Material Changes
The primary material event is the confirmation of the record date for CVR holders. Shareholders of record as of July 16, 2026, are entitled to one CVR for each share of Common Stock held. These CVRs entitle holders to a pro rata portion of the $30.0 million Milestone Payment if the FDA milestone is achieved by the expiration date.
Outlook, Risks, and Contingencies
Management Commentary and Terms:
- Payment Timing: If the Milestone is achieved and a Change of Control occurs, payment is due on the earlier of the Change of Control date or 90 days following a Monetization Event. If no Monetization Event occurs by the Expiration Date, CVRs remain in effect until the Milestone Payment is made in full, payable 90 days after the Monetization Event.
- Transferability: CVRs are generally not transferable, not certificated, and will not be registered with the SEC or listed on any exchange.
Risks and Contingencies:
- The $30.0 million payment is contingent upon regulatory approval (Priority Review Voucher) for briquilimab, which is not guaranteed.
- The payment is subject to specific definitions of "Change of Control" and "Monetization Event" as outlined in the CVR Agreement.
Investor Verification Checklist
- Verify the specific terms of the "Monetization Event" and "Change of Control" in the CVR Agreement (Exhibit F to the Merger Agreement filed as Exhibit 2.1 to the July 16, 2026 Form 8-K).
- Confirm the current development status of briquilimab and the likelihood of receiving a Priority Review Voucher by December 31, 2028.
- Review the non-transferability restrictions of the CVRs to understand liquidity implications for shareholders.
- Check for any subsequent filings regarding the status of the Kira Pharmaceuticals acquisition integration.